赞努布鲁丁尼布加西塔拉宾在耐火性/复发性初级中枢神经系统淋巴瘤患者中
Zhiguang Lin1, Jingjing Ma2, Yan Ma2
1Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China, zhiguang_lin@163.com.
Acta haematologica
|February 26, 2024
概括
这项研究表明,扎努布鲁丁尼布加上细胞arabine 对于耐火性或复发性中枢神经系统原发性淋巴瘤 (PCNSL) 有效. 组合疗法在患有r/r PCNSL的患者中显示了64.7%的总体应答率,并具有可管理的副作用.
科学领域:
- 神经瘤学神经瘤学
- 血液学 血液学 血液学
- 临床试验 临床试验
背景情况:
- 初级中枢神经系统淋巴瘤 (PCNSL) 是一种罕见的,侵袭性的非霍奇金淋巴瘤亚型.
- 目前还没有确立治疗耐火性或复发性PCNSL (r/r PCNSL) 患者的治疗标准.
研究的目的:
- 评估扎努布鲁丁尼布与细胞氨基酸联合治疗r/r PCNSL的疗效和安全性.
- 评估这一患者群体的整体应答率,无进展生存率和整体生存率.
主要方法:
- 进行了一项前性单臂II期临床试验.
- 34名患有r/r PCNSL的患者接受了高剂量的cytarabine和zanubrutinib,长达6个周期.
- 这项研究遵循西蒙的两阶段设计,并以#ChiCTR2000039229.9注册.
主要成果:
- 总体应答率为64.7%,完全缓解率为47.1%.
- 中位数无进展生存时间为4.5个月,中位数总生存时间为18个月.
- 最常见的不良事件是血小板缺血 (55.9%),没有与治疗相关的死亡.
结论:
- 赞努布鲁丁尼布加上细胞氨基酸在治疗r/rPCNSL方面表现出显著的疗效.
- 组合疗法为患有这种具有挑战性的疾病的患者提供了可接受的安全性.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
